Myos Rens Tech Cmn (MYOS) 1.67 $MYOS
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer
Marketwire Canada - Wed Sep 07, 11:35AM CDT
Company Also Announces Election of Victor Mandel to Board of Directors
MYOS: 1.67 (-0.03)
MYOS Reports Positive Results From Fortetropin(R) Clinical Study
Marketwired - Fri Apr 22, 2:00PM CDT
MYOS RENS Technology Inc. ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the positive results of a recent clinical study which demonstrated that the daily use of 4 grams of Fortetropin, which is approximately 40% lower than the currently-recommended 6.6 grams dose, results in statistically significant decreases in serum myostatin levels. A plethora of evidence has linked decreases in serum myostatin levels with gains in lean muscle mass.
MYOS: 1.67 (-0.03)
MYOS Corporation Announces Strategic Investment by RENS Technology Inc.
Marketwired - Thu Dec 17, 7:02AM CST
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS)
MYOS: 1.67 (-0.03)
Maintaining Muscle Linked to Preserving Healthy Brain Tissue
Marketwired - Mon Oct 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, highlights new research showing resistance training reduces loss of brain tissue in aging women. Teresa Lui-Ambrose and her team at the Aging, Mobility, and Cognitive Neuroscience Laboratory at the University of British Columbia examined the effects of resistance training on the aging brain. Women ages 65-75 were randomized to resistance training vs. a control group of stretching and balance exercise. After 52 weeks, women who performed resistance training twice per week had less white matter loss, as measured by MRI, compared to the control group.
MYOS: 1.67 (-0.03)
MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations
Marketwired - Mon Oct 19, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, highlights a new report from Credit Suisse on "Fat: the New Health Paradigm," showing the importance of fat in our diet. For several decades, fat has been blamed for heart disease and the obesity epidemic. A review of the research during this time calls into question the role that fat plays on our overall health. Eggs in particular have been thought to be associated with increased cholesterol and increased risks of heart disease. A more thorough review of the research behind these claims has brought new insights into the overall health benefits and low risks associated with the consumption of eggs. This has translated into an increased demand from consumers for many products, especially eggs. The overall demand for fat will increase over the next few decades and in particular; the egg market is expected to grow at 4 to 5% per year for the next two decades.
MYOS: 1.67 (-0.03)
Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors
PR Newswire - Thu Oct 01, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" today announced the appointment of Robert Hariri, MD, PhD to its Board of Directors.
CYRX: 2.07 (+0.05), MYOS: 1.67 (-0.03), CELG: 110.41 (+0.83), CELGZ: 1.20 (-0.05)
MYOS Corporation to Host Conference Call to Discuss Management Highlights
Marketwired - Fri Aug 14, 3:45PM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced that it filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (the "Form 10-Q" with the Securities and Exchange Commission today. The Form 10-Q may be accessed via the 'SEC Filings' page of the Investor Relations section of the Company's corporate web site at www.myoscorp.com
MYOS: 1.67 (-0.03)
MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App
Marketwired - Wed Jul 22, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the launch of the new Re Muscle Health(TM) website and HealthTrac app, providing customers the ability to set and track health and exercise goals, monitor diets and dietary programs, set consumption reminders and search and save hundreds of recipes.
MYOS: 1.67 (-0.03)
MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments
Marketwired - Wed Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today issued the following letter to shareholders from the Company's Board of Directors.
MYOS: 1.67 (-0.03)
MYOS wins Health Canada's approval for fortetropin as a medicinal ingredient in finished products
M2 - Fri May 29, 3:00AM CDT
Biotherapeutics company MYOS Corporation (NASDAQ:MYOS) stated on Thursday that Health Canada has reviewed and approved its proprietary ingredient Fortetropin for sale in powder dose form in Canada.
MYOS: 1.67 (-0.03)
MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R)
Marketwire Canada - Thu May 28, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that Health Canada, has reviewed and approved Fortetropin(R), the Company's proprietary ingredient, for sale in powder dose form in Canada. Fortetropin is the first fertilized egg yolk powder ingredient to be approved by Health Canada and issued a Natural Product Number.
MYOS: 1.67 (-0.03)
MYOS Corporation Initiates Marketing Plan for Re Muscle Health(TM) Products
Marketwired - Tue May 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that it has engaged Media Horizons Inc. to prepare and manage a direct marketing campaign relying on digital and social media, among other techniques, for its Re Muscle Health(TM) products.
MYOS: 1.67 (-0.03)
Astronaut Buzz Aldrin Relies on Re Muscle Health(TM) Products to Help Rebuild, Rejuvenate and Maintain Lean Muscle
Marketwired - Tue May 19, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that astronaut Dr. Buzz Aldrin, a paid member of the Company's board of directors and spokesman, uses Re Muscle Health(TM) products daily along with regular exercise to help maintain lean muscle at the age of 85.
MYOS: 1.67 (-0.03)
Where are the Investors Headed: Complementary Research on Ladder Capital, New York REIT, J.G. Wentworth, Pain Therapeutics and MYOS Corp.
PR Newswire - Fri May 15, 7:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
LADR: 13.37 (+0.12), JGW: 0.45 (+0.06), NYRT: 9.25 (+0.10), MYOS: 1.67 (-0.03), PTIE: 2.81 (+0.02)
MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights
Marketwired - Tue May 12, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company" (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it plans to file its Quarterly Report on Form 10-Q for the quarter that ended March 31, 2015 (the "Form 10-Q" with the Securities and Exchange Commission before market open on Thursday, May 14th, 2015. The Form 10-Q may be accessed via the SEC filings page of the Investor Relations section of the MYOS corporate web site at www.myoscorp.com.
MYOS: 1.67 (-0.03)
MYOS initiates clinical study in subjects to examine the effects of Fortetropin on plasma myostatin levels at various dose levels
M2 - Tue May 12, 4:08AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) announced on Monday the launch of a dose response clinical study of Fortetropin in modestly resistance trained subjects to examine its effects on plasma myostatin levels at various levels to enhance muscle growth .
MYOS: 1.67 (-0.03)
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer
Marketwire Canada - Wed Sep 07, 11:35AM CDT
Company Also Announces Election of Victor Mandel to Board of Directors
MYOS: 1.67 (-0.03)
MYOS Reports Positive Results From Fortetropin(R) Clinical Study
Marketwired - Fri Apr 22, 2:00PM CDT
MYOS RENS Technology Inc. ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the positive results of a recent clinical study which demonstrated that the daily use of 4 grams of Fortetropin, which is approximately 40% lower than the currently-recommended 6.6 grams dose, results in statistically significant decreases in serum myostatin levels. A plethora of evidence has linked decreases in serum myostatin levels with gains in lean muscle mass. MYOS: 1.67 (-0.03)
MYOS Corporation Announces Strategic Investment by RENS Technology Inc.
Marketwired - Thu Dec 17, 7:02AM CST
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS) MYOS: 1.67 (-0.03)
Maintaining Muscle Linked to Preserving Healthy Brain Tissue
Marketwired - Mon Oct 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, highlights new research showing resistance training reduces loss of brain tissue in aging women. Teresa Lui-Ambrose and her team at the Aging, Mobility, and Cognitive Neuroscience Laboratory at the University of British Columbia examined the effects of resistance training on the aging brain. Women ages 65-75 were randomized to resistance training vs. a control group of stretching and balance exercise. After 52 weeks, women who performed resistance training twice per week had less white matter loss, as measured by MRI, compared to the control group. MYOS: 1.67 (-0.03)
MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations
Marketwired - Mon Oct 19, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, highlights a new report from Credit Suisse on "Fat: the New Health Paradigm," showing the importance of fat in our diet. For several decades, fat has been blamed for heart disease and the obesity epidemic. A review of the research during this time calls into question the role that fat plays on our overall health. Eggs in particular have been thought to be associated with increased cholesterol and increased risks of heart disease. A more thorough review of the research behind these claims has brought new insights into the overall health benefits and low risks associated with the consumption of eggs. This has translated into an increased demand from consumers for many products, especially eggs. The overall demand for fat will increase over the next few decades and in particular; the egg market is expected to grow at 4 to 5% per year for the next two decades. MYOS: 1.67 (-0.03)
Cryoport Appoints Robert Hariri, MD, PhD to its Board of Directors
PR Newswire - Thu Oct 01, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company"
today announced the appointment of Robert Hariri, MD, PhD to its Board of Directors. CYRX: 2.07 (+0.05), MYOS: 1.67 (-0.03), CELG: 110.41 (+0.83), CELGZ: 1.20 (-0.05)
MYOS Corporation to Host Conference Call to Discuss Management Highlights
Marketwired - Fri Aug 14, 3:45PM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced that it filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (the "Form 10-Q" with the Securities and Exchange Commission today. The Form 10-Q may be accessed via the 'SEC Filings' page of the Investor Relations section of the Company's corporate web site at www.myoscorp.com MYOS: 1.67 (-0.03)
MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App
Marketwired - Wed Jul 22, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the launch of the new Re Muscle Health(TM) website and HealthTrac app, providing customers the ability to set and track health and exercise goals, monitor diets and dietary programs, set consumption reminders and search and save hundreds of recipes. MYOS: 1.67 (-0.03)
MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments
Marketwired - Wed Jun 24, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, today issued the following letter to shareholders from the Company's Board of Directors. MYOS: 1.67 (-0.03)
MYOS wins Health Canada's approval for fortetropin as a medicinal ingredient in finished products
M2 - Fri May 29, 3:00AM CDT
Biotherapeutics company MYOS Corporation (NASDAQ:MYOS) stated on Thursday that Health Canada has reviewed and approved its proprietary ingredient Fortetropin for sale in powder dose form in Canada.
MYOS: 1.67 (-0.03)
MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R)
Marketwire Canada - Thu May 28, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that Health Canada, has reviewed and approved Fortetropin(R), the Company's proprietary ingredient, for sale in powder dose form in Canada. Fortetropin is the first fertilized egg yolk powder ingredient to be approved by Health Canada and issued a Natural Product Number. MYOS: 1.67 (-0.03)
MYOS Corporation Initiates Marketing Plan for Re Muscle Health(TM) Products
Marketwired - Tue May 26, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that it has engaged Media Horizons Inc. to prepare and manage a direct marketing campaign relying on digital and social media, among other techniques, for its Re Muscle Health(TM) products. MYOS: 1.67 (-0.03)
Astronaut Buzz Aldrin Relies on Re Muscle Health(TM) Products to Help Rebuild, Rejuvenate and Maintain Lean Muscle
Marketwired - Tue May 19, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that astronaut Dr. Buzz Aldrin, a paid member of the Company's board of directors and spokesman, uses Re Muscle Health(TM) products daily along with regular exercise to help maintain lean muscle at the age of 85. MYOS: 1.67 (-0.03)
Where are the Investors Headed: Complementary Research on Ladder Capital, New York REIT, J.G. Wentworth, Pain Therapeutics and MYOS Corp.
PR Newswire - Fri May 15, 7:20AM CDT
Editor Note: For more information about this release, please scroll to bottom.
LADR: 13.37 (+0.12), JGW: 0.45 (+0.06), NYRT: 9.25 (+0.10), MYOS: 1.67 (-0.03), PTIE: 2.81 (+0.02)
MYOS Corporation to Host Conference Call to Discuss Quarterly Update and Management Highlights
Marketwired - Tue May 12, 6:35AM CDT
MYOS Corporation ("MYOS" or the "Company"
(NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it plans to file its Quarterly Report on Form 10-Q for the quarter that ended March 31, 2015 (the "Form 10-Q" with the Securities and Exchange Commission before market open on Thursday, May 14th, 2015. The Form 10-Q may be accessed via the SEC filings page of the Investor Relations section of the MYOS corporate web site at www.myoscorp.com. MYOS: 1.67 (-0.03)
MYOS initiates clinical study in subjects to examine the effects of Fortetropin on plasma myostatin levels at various dose levels
M2 - Tue May 12, 4:08AM CDT
Biotherapeutics company MYOS (NASDAQ:MYOS) announced on Monday the launch of a dose response clinical study of Fortetropin in modestly resistance trained subjects to examine its effects on plasma myostatin levels at various levels to enhance muscle growth .
MYOS: 1.67 (-0.03)
